(Q34581192)

3 August 2017

title

Etodolac: an overview of a selective COX-2 inhibitor (English)

1 reference

3 August 2017

Jones RA

1

1 reference

3 August 2017

publication date

1 January 1999

1 reference

3 August 2017

1 reference

3 August 2017

volume

7

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

269-275

1 reference

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

3 August 2017

cites work

1 reference

12 December 2020

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

1 reference

12 December 2020

Large-scale open trials with etodolac (Lodine) in France: an assessment of safety

1 reference

12 December 2020

Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays

1 reference

12 December 2020

Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis.

1 reference

12 December 2020

An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa

1 reference

12 December 2020

Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells

1 reference

12 December 2020

Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins

1 reference

12 December 2020

10.1007/S10787-999-0010-3

Identifiers

DOI

1 reference

3 August 2017

1 reference